A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
Conditions
Alzheimer Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft GmbH, Salzburg, State of Salzburg, Austria
University Hospital Graz, Graz, Styria, Austria
Medical University Innsbruck, Innsbruck, Austria
Contact: Study coordinator (Samuel Labrecque, MSc) · Samuel.Labrecque@tirol-kliniken.at · 0043512504Contact: Principal Investigator (Atbin Djamshidian- Tehrani)Medical University Vienna, Vienna, Austria
Contact: Principal Investigator (Elisabeth Stögmann)Clinic Altenburger Land GmbH, Altenburg, Germany
Contact: Study coordinator (Conny Sternitzky) · conny.sternitzky@klinikum-altenburgerland.de · 00493447523211Contact: Principal Investigator (Jörg Berrouschott)Zentrum fuer klinische Forschung Dr. I. Schoell GmbH, Bad Homburg, Germany
University Clinic Köln, Cologne, Germany
Contact: Principal Investigator (Özgür Onur)Universitaetsmedizin Goettingen, Göttingen, Germany
Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Germany
SANOS Clinic, Ratingen, Germany
Contact: Principal Investigator (Jens Harmel)
Study leads
Manfred Windisch, PhD
Study Chair
NSC-Therapeutics GmbH